AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. 11:35:27 2024-04-23 am EDT 5-day change 1st Jan Change
11,268 GBX +0.16% Intraday chart for AstraZeneca PLC +2.21% +6.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AstraZeneca's Voydeya Approved as Add-on Therapy in Europe for Blood Disorder MT
ASTRAZENECA : JP Morgan reaffirms its Buy rating ZD
AstraZeneca: Voydeya approved in the EU as a treatment for HPN CF
AstraZeneca Obtains EU Approval for Voydeya as Add-on Treatment for Rare Blood Disease MT
European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations MT
AstraZeneca: presents new data at ECCMID CF
The market is pinning its hopes on earnings reports Our Logo
ASTRAZENECA : Receives a Buy rating from JP Morgan ZD
ANALYST RECOMMENDATIONS : Las Vegas Sands, Regeneron, Kinder Morgan, Rivian, Royal Caribbean... Our Logo
Market sentiment sours Our Logo
ASTRAZENECA : Deutsche Bank returns to 'Hold CF
Deutsche Bank Upgrades AstraZeneca to Hold from Sell, Lifts PT MT
Astrazeneca plc Announces IMFINZI Plus Chemotherapy Doubled Overall Survival Rate At Three Years for Patients with Advanced Biliary Tract Cancer in Topaz-1 Phase III Trial CI
ASTRAZENECA : Deutsche Bank drops its Sell rating ZD
ANALYST RECOMMENDATIONS : AMD, Colgate, Fair Isaac, Tyson Foods, AstraZeneca Our Logo
RBC raises Admiral; Barclays cuts Phoenix Group AN
AstraZeneca: improvements in biliary tract cancer CF
AstraZeneca's hails Imfinzi survival data on cancer form AN
AstraZeneca's Biliary Tract Cancer Combo Improves Overall Survival in Late-stage Trial MT
Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors CI
AstraZeneca: expects a sharp rise in kidney disease CF
ASTRAZENECA : Barclays reiterates its Buy rating ZD
Adherium’s Hailie Smartinhaler Secures FDA Approval for Use with AstraZeneca's Airsupra and Breztri Inhalation Devices MT
Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin... Our Logo
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says DJ
Chart AstraZeneca PLC
More charts
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
138.8 USD
Average target price
161.5 USD
Spread / Average Target
+16.37%
Consensus
  1. Stock Market
  2. Equities
  3. AZN Stock
  4. News AstraZeneca PLC
  5. AstraZeneca Says Fasenra Shows Supports Corticosteroids Remission in Eosinophilic Granulomatosis with Polyangiitis